ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Alkermes plc. publishes a filing, an earnings call transcript or a press release.
Get ALKS alertsThe proxy statement of Alkermes plc. reports total compensation of $2,790,694 for Todd Nichols in fiscal 2025, including a base salary of $614,869. Disclosed compensation is on record for 2 fiscal years. Todd Nichols has spoken on 3 earnings calls across 1 company, most recently for Alkermes plc. on November 3, 2026. Alkermes plc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Alkermes plc. includes Blair C. Jackson (CEO, CFO and COO), Mr. Richard F. Pops (CEO), Iain M. Brown (CFO and Chief Accounting Officer) and 7 others.
“I'm pleased to report that we delivered strong performance across our commercial portfolio in the third quarter, reflecting contributions across addiction, psychiatry, and sleep medicine.”
“I'm pleased to report that we're off to a strong start to the year with first quarter performance ahead of our expectations and solid execution across the commercial organization.”
“2025 was another strong year of discipline execution against our commercial strategy. I am pleased that we delivered at the high end of the increased guidance ranges we provided in October for our proprietary products, driven by strong performance across all three brands.”
Proxy statement
Start not stated–present
Last confirmed April 6, 2026
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alkermes plc. (ALKS) | Senior Vice President, Chief Commercial Officer | $614,869 | $2,790,694 |
| 2024 | Alkermes plc. (ALKS) | Senior Vice President, Chief Commercial Officer | $596,960 | $3,319,071 |